{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for valproic root_Display\ Name in Display Name (approximate match)
Status:
US Previously Marketed
Source:
Solution of Potassium Arsenite U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Solution of Potassium Arsenite U.S.P.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Arsenite ion is a form of inorganic trivalent arsenic. It is derived from arsenous acid and known mainly for forming the basis of Fowler's solution (1% potassium arsenite (KAsO2). Fowler's solution has had a fascinating history in medicine during the past 200 years. The use of Fowler's solution was first described and published as a treatment for malaria and syphilis in the late 1700s. Many clinical applications for Fowler's solutions have been studied and utilized over the years, but toxicities have limited its utility. Even so, arsenic trioxide, chemically related to Fowler's solution, was approved by the US Food and Drug Administration for treating acute promyelocytic leukemia. The chronic arsenic exposure is a cause of immense health distress as it accounts for the increased risk of various disorders such as cardiovascular abnormalities, diabetes mellitus, neurotoxicity, and nephrotoxicity. In addition, the exposure to arsenic has been suggested to affect the liver function and to induce hepatotoxicity. Moreover, few studies demonstrated the induction of carcinogenicity especially cancer of the skin, bladder, and lungs after the chronic exposure to arsenic.
Status:
US Previously Marketed
Source:
AM PLUS IMPROVED SODIUM MOLYBDATE by ROERIG
(1961)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Molybdic acid refers to hydrated forms of molybdenum trioxide. There is no information related to the biological and pharmacological application of molybdic acid. It is known, that this substance is used as heterogeneous catalysts.
Status:
US Previously Marketed
Source:
Bromauric Acid N. F.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Gold trichloride is used as a catalyst in synthesis of new compounds. It was shown that gold trichloride was not the marker of contact allergy and could not be recommended in patch testing.
Status:
US Previously Marketed
Source:
Bromauric Acid N. F.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Gold trichloride is used as a catalyst in synthesis of new compounds. It was shown that gold trichloride was not the marker of contact allergy and could not be recommended in patch testing.
Status:
US Previously Marketed
Source:
Bromauric Acid N. F.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Gold trichloride is used as a catalyst in synthesis of new compounds. It was shown that gold trichloride was not the marker of contact allergy and could not be recommended in patch testing.
Status:
US Previously Marketed
Source:
AM PLUS IMPROVED SODIUM MOLYBDATE by ROERIG
(1961)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Molybdic acid refers to hydrated forms of molybdenum trioxide. There is no information related to the biological and pharmacological application of molybdic acid. It is known, that this substance is used as heterogeneous catalysts.
Status:
US Previously Marketed
Source:
Bromauric Acid N. F.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Gold trichloride is used as a catalyst in synthesis of new compounds. It was shown that gold trichloride was not the marker of contact allergy and could not be recommended in patch testing.
Status:
US Previously Marketed
Source:
Oleic Acid U.S.P.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Elaidic acid is the 9-trans isomer of oleic acid. It is a monounsaturated trans-fatty acid, which can be found in partially hydrogenated cooking oils. It was revealed, that elaidic acid inhibits HHT and HETE formation in human platelets incubated with arachidonic acid. Also was shown, that trans oleic acid increased plasma CETP activity, which increases low-density lipoprotein (LDL) cholesterol and decreases high-density lipoprotein (HDL).
Status:
US Previously Marketed
Source:
Sodium Bromide U.S.P.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Hydrobromic acid is a useful reagent for generating organobromine compounds. It was shown that hydrobromic acid could initiate or exacerbate inflammatory pulmonary disease.
Status:
US Previously Marketed
Source:
Gallic Acid U.S.P.
(1921)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Gallic acid is a polyphenol found in a variety of foods and herbs. Several studies have shown thta gallic acid has neuroprotective and anti-oxidant properties and can be a promising candidate for the treatment of cancer, cardiovascular diseases, neurodegenerative disorders, fatty liver disease and many others. Gallic acid acts by protecting cells against oxidative damage caused by reactive species often encountered in biological systems including, hydroxyl, superoxide and peroxyl and the non-radicals, hydrogen peroxide and hypochlorous acid. However, its ability to induce apoptosis, is mainly associated with its prooxidant, rather than antioxidant behavior.